Which group achieves 41% more weight loss on GLP-1s like Mounjaro: study - New York Post

What the report says

The New York Post reported on new research suggesting women with overweight or obesity lose more weight than men while taking tirzepatide, the active ingredient in Mounjaro. Citing a study published in the journal Obesity, the Post said women who remained on treatment for 15 months lost about 15% of their body weight, compared with nearly 11% among men.

According to the report, researchers also assessed other factors linked to weight-loss outcomes. Participants younger than 45 lost more weight than those older than 60, but sex appeared to be a stronger predictor than age. The Post said greater reductions were also associated with not having Type 2 diabetes, no prior use of weight-loss drugs and taking a higher tirzepatide dose.

The article placed the findings in the broader context of GLP-1 medicines, a class that includes tirzepatide and semaglutide-based drugs such as Ozempic. It noted that women have often faced biological barriers to weight loss, including differences in muscle mass, hormones and fat storage, but that some GLP-1 studies have shown larger average losses among women than men. A cited meta-analysis of nearly 20,000 people reportedly found women lost about 11% of body weight on drugs such as semaglutide and dulaglutide, compared with about 7% for men.

The Post said possible explanations include slower drug clearance in women and hormonal effects, including estrogen’s role in appetite, satiety, energy use and insulin sensitivity. The article also referenced other studies examining possible GLP-1 links to lower breast cancer risk, but did not present those findings as part of the new Obesity study.